Intracoronary stent: An approach to the cost/effectiveness analysis;Prótesis intracoronarias (stent): Una aproximación al análisis de coste-efectividad

Revista Espanola de Cardiologia

Volumn 50, Issue SUPPL. 2, 1997, Pages 83-94

  Romo, Andrés Iñíguez ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b U Hemodinanuca y Cardiol I   (Spain)

Author keywords

Angioplastia coronaria; Coste efectividad Stent; Costes

Indexed keywords

CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; REVIEW; STENT;

CORONARY DISEASE; CORONARY VESSELS; COST-BENEFIT ANALYSIS; HUMANS; STENTS;

EID: 0030631626     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Mainar V, Gómez Recio M, Martínez Elbal L, Pan M. Registro de actividad de la Sección de Hemodinámica y Cardiología Intervencionista en los años 1990 y 1991. Rev Esp Cardiol 1992; 45: 622-626.
2. Zueco J, García E, Elízaga J, Serra A. Registro de actividad de la Sección de Hemodinãmica y Cardiología Intervencionista del año 1995. Rev Esp Cardiol 1996; 49: 714-722.
3. Opol EJ, Ellis SG, Cosgrove DM et al. Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation 1993; 87: 1.489-1.497.
4. Lázaro P. Angioplastia coronaria y cirugía coronaria: algunas consderaciones socioeconómicas Rev Esp Cardiol 1993, 46: 7-20.
5. OECD, OECD HEALTH DATA. A software package for the international comparison of health care systems. Version 1.5. París, 1993.
6. Drummond M, Stoddart G, Labelle, Cushman R. Health economics: an introduction for clinicians. Ann Intern Med 1987; 107: 88-92.
7. Mooney GH. Economic aspects of the global programme for appropriate health care technology. Health Economics Research Unit, Department of Community Medicine. Aberdeen. Reino Unido, 0068S. 1986.
8. Gudex C, Kind P. The QALY Toolkit. Discussion paper 38. Centre for Health Economics. Reino Unido, Universidad de York, 1987.
9. Kind P. The design and construction of quality of life measures. Discussion paper 43. Centre for Health Economics. Reino Unido, Universidad de York, 1988.
10. The EuroQol Group. EuroQol - a new facility for the measurement for health-related quality of life Health Policy 1990; 16: 199-208.
11. RAND Health Sciences Program. RAND 36-Item Health Survey 1.0. RAND, Santa Monica, CA, EE.UU., 1992.
12. Preference based outcome measures for economic evaluation of drug interventions. Quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). Pharmaco Economics 1992, 1: 338-345.
13. Elízaga J, García E, Zueco J, Serra A. Registro de actividad de la Sección de Hemodinámica y Cardiología Intervencionista del año 1944. Rev Esp Cardiol 1995; 48: 783-791.
14. Iñíguez A. Análisis de costes en hemodinámica y cardiología intervencionista: cuánto gastamos, en qué lo gastamos y por qué. Rev Esp Cardiol 1995; 48: 255-259.
15. Brook RH, Lohr KN. Will we need to ration effective health care? Iss Sci Technol 1986; 3: 68-77.
16. Back N. Research, audit, and education. Br Med J 1992; 304: 698-700.
17. Luengo S, Lázaro P, Guash MF. Investigación en Servicios de Salud financiada por el FIS. Madrid: Unidad de Investigación en Servicios de Salud, 1993.
18. Hilborne LH, Leape LL, Kahan JP, Park RE, Kamberg CJ, Brook RH. Percutaneous transluminal coronary angioplasty. A literature review and ratings of appropiateness and necesity. RAND JRA01, 1991.
19. Pennsylvania Heath Care Cost Containment Council. A consumer guide to coronary bypass graft surgery. Harrisburg. PA. 1993.
20. Dick RJ, Popma JJ, Muller DWM, Burek KA, Topol EJ. In-hospital costs associated with new percutaneous coronary devices. Am J Cardiol 1991; 68: 879-885.
21. Cohen DJ, Breall JA, Ho KKL, Weintraub RM, Kuntz RE, Wenstein MC et al. Economics of elective coronary revascularization. Comparison of cost and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol 1993; 22: 1.052-1.059.
22. Wong JB, Sonnenberg FA, Salen DM, Pauker ST. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990; 113: 852-871.
23. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation 1982; 66 (Supl 3): 56-66.
24. Williams A. Economics of coronary artery bypass grafting. Br Med J 1985; 291: 326-329.
25. Leape LL, Hilbome LH, Bernstein SJ. Coronary artery bypass graft. A literature review and ratings of appropiateness and neccessity. RAND JRA-02, 1991.
26. Weintraub WS, Mauldin PD, Becker E, Korninsky AS, King SB III. A comparison of the cost and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty versus Surgery trial (EAST). Circulation 1995; 92: 2.831-2.840.
27. Sacristan JA, Soto J, Reviriego J, Galende I. Farmacoeconomía: el cálculo de la eficiencia. Med Clin (Barc) 1994; 103: 143-149.
28. Department of clinical epidemiology and biostatistics, McMaster University Health Sciences Centre, Hamilton, Ont How to read clinical journals VII: To understand an economic evaluation (part A). Can Med Assoc J 1984; 130: 1.428-1.433.
29. Department of clinical epidemiology and biostatistics, McMaster University Health Sciences Centre, Hamilton, Ont. How to read clinical journals VII: To understand an economic evaluation (part B). Can Med Assoc J 1984; 130: 1.542-1.549.
30. Fletcher RH. The cost of clinical trials. JAMA 1989; 262: 1.842.
31. Detsky AS. Are clinical trial a cost-effective investment? JAMA 1989; 262: 1.795-1.800.
32. Hillman AL, Eisemberg JM, Pauly MV, Bloom BS. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1.362-1.365.
33. Udvarheyi IS, Colditz GA, Rai A, Epstein MP. Cost-effectiveness analysis in the medical literature. Are the methods being used correctly? Ann Intern Med 1992; 116: 238-244.
34. Doubilet P, Weinstein M, McNeill BJ. Use and misuse of the term "cost-effectiveness" in medicine. N Engl J Med 1986; 314: 253-256.
35. Lee JT, Sánchez LA. Interpretation of "cost-effective" and soundness of economic evaluation in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2.622-2 627.
36. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992; 49: 1.741-1.747.
37. Broadhead WG, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiology survey. JAMA 1990; 264: 2.524-2.528.
38. Drummond MF, Stoddart G, Labelle R, Cushman R. Health economic an introduction for clinicians. Ann Intern Med 1987; 107: 88-92.
39. Drummond MF. The role of economic evaluation in the pricing of modern pharmaceutical products. Pharmaceutical Times 1989/1990; diciembre 32: 3; enero: 10:1; febrero 19.9; marzo 38.40.
40. Drummond MF. The role of economic evaluation in the pricing of modern pharmaceutical products. Pharmaceutical Times 1989/1990; diciembre 32: 3; enero: 10:1; febrero 19.9; marzo 38.40.
41. Drummond MF. The role of economic evaluation in the pricing of modern pharmaceutical products. Pharmaceutical Times 1989/1990; diciembre 32: 3; enero: 10:1; febrero 19.9; marzo 38.40.
42. Drummond MF. The role of economic evaluation in the pricing of modern pharmaceutical products. Pharmaceutical Times 1989/1990; diciembre 32: 3; enero: 10:1; febrero 19.9; marzo 38.40.
43. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1.728-1.733.
44. Eisenberg JM. Clinical economics. A guide to economic analysis of clinical practice. JAMA 1989; 262: 2.879-2.866.
45. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. Cincinnati: Harvey Whitney, 1991.
46. Drummond MF, Stoddart GL. Economic analysis alongside clinical trials: revisiting the methodological issues. Intern J Tech Ass Health Care 1991; 7: 561-573.
47. Weinstein MC, Stason WB. Foundations and cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-721.
48. Fitzpatrick R, Fletcher A, Gore S, Jones D. Quality of life measures in health care. I: Applications and issues in assessment. Br Med J 1992; 305: 1.074-1.077.
49. Fletcher A, Gore S, Jones D, Fitzpatrick R. Quality of life measures in health care. II: Design, analysis and interpretation. Br Med J 1992; 305: 1.145-1.148.
50. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-481.
51. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559-575.
52. Mehrez A, Gafni A. Quality adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9: 142-149.
53. Subdirección General de Prestaciones y evaluación de tecnologías sanitarias. Propuesta de estandarización de algunos aspectos metodológicos de los análisis coste-efectividad y coste utilidad en la evaluación de tecnologías y programas sanitarios. Madrid: Ministerio de Sanidad y Consumo, febrero de 1994.
54. Detsky AS, Naglie GN. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147-154.
55. Macaya C, Serruys P, Ruygrok P, Suryapranata H, Mast G, Klugman S et al. Continued benefit of coronary stenting versus ballon angioplasty: one-year clinical follow-up op Benestent trial. J Am Coll Cardiol 1996; 27: 255-261.
56. Fernández Avilés F, Alonso J, Durán JM, Gimeno F, Muñoz JC, De la Fuente L et al. Subabute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenging under a new antithrombotic regime. J Am Coll Cardiol 1996; 27: 22-29.
57. Hall P, Nakamura SH, Maiello L, Iton A, Blengino S, Martini G et al. A randomized comparison of combined ticlopidine an aspirin therapy versus aspirin therapy alone after successful intravascular-guided stent implantation. Circulation 1996; 93: 215-222.
58. Cohen DJ, Breall JA, Ho KKL, Kuntz RE, Goldman L, Baim DS et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. Circulation 1994; 89: 1.859-1.874.
59. Tengs TO, Adams ME, Pliskin JS. Five-hundredlefe saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369-390.
60. Drummond MF. Economic evaluation and the rational diffusion and use of health technology. Health Policy 1987; 7: 309-324.
61. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732-739.
62. Kupperman M, Luce BR, McGovem B, Podrid PJ, Bigger JT, Ruskin JN. An analysis of the cost-effectiveness of the implantable defibrilator. Circulation 1990; 81: 91-100.
63. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NAM, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992; 19: 1.323-1.334.
64. Martinez Bengoechea MJ, Errecalde MF, Jaio N, Sáinz de Rozas C, Arana A, Ibarra O. Coste-efectividad de alteplasa versus estreptoquinasa en el infarto de miocardio. Farmacoeconomía 1994; 10: 26-34.
65. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, Chuang YC et al. Vascular complications after balloon and new device angioplasty. Circulation 1993; 88: 1.569-1.578.
66. Charles ED, Agraval SK, Cannon AD, Dean LS, Baxley WA, Roubin GS. Projected cost saving for coronary stenting instead of emergency CABG for acute closure complicating PTCA [resumen] J Am Coll Cardiol 1993; 21: 177A.
67. Serruys PW, Luijten HE, Beatt KJ, Gesuskens R, De Feyter PJ, Van der Brand M et al. Incidence of restenosis after successful coronary angioplasty: a time related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-371.
68. Alonso M, Tascón J, Andreu J, Albarrán A. Análisis de costes en hemodinámica. Estudio multicéntrico basado en consumes reales. Rev Esp Cardiol 1995; 48: 245-254.
69. Bresco S, Oriol A, García J, Augé JM, Crexels C. Coste de la ACTP en un hospital terciario de nuestro medio. Rev Esp Cardiol 1985; 38 (Supl 1): 79-82.
70. Iñíguez A, Serrano C, Díaz Fernández JL, Córdoba M, Ternes JL, Villalobos E et al. Análisis de costes reales de la angioplastia coronaria en España. Rev Esp Cardiol 1993; 46 (Supl 1): 5.